Navidea Biopharmaceuticals’ NAV4694 β-Amyloid Imaging Agent to Be Used in Alzheimer’s Disease Studies by Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) Jul 16, 2013
Navidea Biopharmaceuticals to Co-Sponsor Alzheimer’s Imaging Consortium at Alzheimer’s Association International Conference Jul 11, 2013
Navidea Biopharmaceuticals Initiates Enrollment in Global Phase 3 Trial of NAV4694 PET Imaging Agent Jun 27, 2013
Navidea Biopharmaceuticals Closes $25 Million Debt Financing with GE Capital, Healthcare Financial Services Jun 26, 2013
Navidea Biopharmaceuticals Announces Presentation of Meta-Analysis Results of Lymphoseek® and ACOSOG Radiolabeled Colloid in Head and Neck Cancer Jun 12, 2013
Navidea Biopharmaceuticals Announces Results from Lymphoseek® Study on Accuracy of Lymph Node Detection from Injection Time to Surgery Jun 11, 2013
Navidea Biopharmaceuticals Announces Presentation of Results from Two Lymphoseek® and Radiolabeled Colloid Studies in Lymphatic Mapping for Breast Cancer at SNMMI Jun 10, 2013
